Sotera Health(SHC) Newsfilter·2025-02-27 12:00Core Insights - Sotera Health Company reported a decrease in net revenues for the fourth quarter of 2024, down 6.5% to $290 million compared to $310 million in the same period of 2023, with a net income of $12 million or $0.04 per diluted share [2][3] - For the full year 2024, net revenues increased by 4.9% to $1.10 billion, with net income of $44 million or $0.16 per diluted share, marking the 19th consecutive year of revenue growth for the company [3][4] - The company anticipates a revenue growth outlook for 2025 in the range of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, both on a constant currency basis [9][18] Financial Performance - Fourth-quarter 2024 adjusted EBITDA decreased by 8.3% to $153 million, with adjusted earnings per diluted share of $0.21, a decrease of $0.02 from the previous year [2][3] - Full-year 2024 adjusted EBITDA increased by 3.9% to $549 million, with adjusted EPS of $0.70, down $0.02 from 2023 [3][9] - The company had total debt of $2.3 billion and cash and cash equivalents of $277 million as of December 31, 2024, with a net leverage ratio of 3.7x [16][46] Business Segment Performance - In the fourth quarter of 2024, Sterigenics reported net revenues of $179 million, an increase of 4.2% year-over-year, while Nordion's revenues decreased by 28.9% to $57 million due to cobalt harvest timing [5][10] - For full-year 2024, Sterigenics net revenues were $698 million, up 4.6%, and Nordion's revenues increased by 8.0% to $173 million [6][11] - Nelson Labs experienced a revenue decline of 7.3% in the fourth quarter, but for the full year, revenues increased by 3.4% to $229 million [13][14] Governance and Strategic Developments - The company appointed Chris Simon, CEO of Haemonetics, to its board and named Vince Petrella as lead independent director, enhancing its governance structure [4] - The company continues to focus on customer satisfaction, achieving scores over 80%, and has expanded its Sterigenics facility [4]